Search Result

Pathways Recommended:	Metabolic Enzyme/Protease

Results for "

wild-type HIV-1 protease

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HIV (17) HIV Protease (21) Isotope-Labeled Compounds (3) Reference Standards (4) SARS-CoV (5)
By Research Areas:	Cancer (3) Infection (21) Inflammation/Immunology (4) Neurological Disease (1)

Inhibitors & Agonists

Isotope-Labeled Compounds

Targets Recommended: HIV Protease HIV Integrase HIV Virus Protease HCV Protease Protease Activated Receptor (PAR) ClpP TMPRSS6 Calpain Serpin Enteropeptidase Ser/Thr Protease

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14588

Lopinavir Maximum Cited Publications 20 Publications Verification ABT-378	HIV HIV Protease SARS-CoV	Infection Neurological Disease Cancer
Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the **HIV-1 protease, with K_is** of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 14.2 μM .

HY-17040

Darunavir 15+ Cited Publications TMC114; UIC-94017	HIV HIV Protease	Infection Inflammation/Immunology
Darunavir (TMC114), an orally active next generation **HIV protease** inhibitor, has a similar antiviral activity against the mutant and the wild-type viruses. Darunavir (TMC114) is potent against laboratory HIV-1 strains and primary clinical isolates (IC₅₀ = 0.003 μM; IC₉₀ = 0.009 μM) with minimal cytotoxicity .

HY-17041

Darunavir Ethanolate 15+ Cited Publications TMC114 Ethanolate	HIV HIV Protease	Infection
Darunavir ethanolate (TMC114 Ethanolate) is a potent *HIV* protease inhibitor used to treat and prevent HIV/AIDS. Darunavir has a K_i of 1 nM for wild type HIV-1 protease.

HY-107123

TMC310911 1 Publications Verification ASC-09	HIV Protease	Infection
TMC310911 is a potent and orally active **HIV type-1 (HIV-1) protease inhibitor with EC₅₀ values ranged from 2.2 nM to 14.2 nM for wild-type HIV-1. TMC310911 has potent activity against a wide spectrum of recombinant HIV-1** isolates. TMC310911 has strong antiviral activity .

HY-134851

HIV-1 inhibitor-6 1 Publications Verification	HIV	Infection
HIV-1 inhibitor-6 (compound 9), a diheteroarylamide-based compound, is a potent HIV-1 pre-mRNA alternative splicing inhibitor. HIV-1 inhibitor-6 blocks HIV replication. HIV-1 inhibitor-6 is active against wild-type HIV-1IIIB (subtype B, X4-tropic) and HIV-1 97USSN54 (subtype A, R5-tropic) with EC₅₀s of 0.6 μM and 0.9 μM, respectively. HIV-1 inhibitor-6 inhibits HIV strains resistant to agents targeting HIV reverse transcriptase, protease, integrase, and coreceptor CCR5 with EC₅₀s ranging from 0.9 to 1.5 μM .

HY-147650

HIV-1 protease-IN-5	HIV Protease	Infection
HIV-1 protease-IN-5 (Compound 13c) is a **HIV-1 protease inhibitor with an IC₅₀** of 1.64 nM. HIV-1 protease-IN-5 shows remarkable activity against wild-type and DRV-resistant HIV-1 variants .

HY-149936

HIV-1 protease-IN-8	HIV Protease	Infection
HIV-1 protease-IN-8 (compound 34b) is a potent **HIV-1 protease inhibitor with an IC₅₀** value of 0.32 nM. HIV-1 protease-IN-8 displays IC₅₀s of 0.29 μM and 1.90 μM for wild-type HIV-1 (HIV-1_NL4-3) and drug-resistant variant (HIV-1_MDR), respectively. HIV-1 protease-IN-8 displays robust antiviral activity against both wild-type HIV-1 and drug-resistant variant .

HY-171835

DPC 684	HIV HIV Protease	Infection
DPC 684 is a potent and selective **HIV-1 protease inhibitor (IC₉₀ = 5.7-40 nM, Ki = 0.021 nM). DPC 684 competitively inhibits HIV-1 protease** and blocks viral polyprotein cleavage. DPC 684 has low protein binding and broad-spectrum inhibition against a variety of wild-type and mutant **HIV-1 proteases. DPC 684 has low protein binding and broad-spectrum inhibition (IC₉₀** = 1.9-6.3 nM). DPC 684 has research significance for HIV .

HY-150549

HIV-1 protease-IN-6	HIV Protease HIV	Infection Inflammation/Immunology
HIV-1 protease-IN-6 (compound 17d) is a potent **HIV-1 protease inhibitor, with an IC₅₀ of 21 pM and a K_i** of 4.7 pM, respectively. HIV-1 protease-IN-6 exhibits potent antiviral activity to DRV (darunavir)-resistant variant, even more than wild type virus .

HY-14588S1

Lopinavir-d8	Isotope-Labeled Compounds HIV HIV Protease SARS-CoV	Infection
Lopinavir-d₈ (ABT-378-d₈) is the deuterium labeled Lopinavir. Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 14.2 μM .

HY-17040R

Darunavir (Standard) TMC114 (Standard); UIC-94017 (Standard)	HIV HIV Protease Reference Standards	Infection Inflammation/Immunology
Darunavir (Standard) is the analytical standard of Darunavir. This product is intended for research and analytical applications. Darunavir (TMC114), an orally active next generation HIV protease inhibitor, has a similar antiviral activity against the mutant and the wild-type viruses. Darunavir (TMC114) is potent against laboratory HIV-1 strains and primary clinical isolates (IC50 = 0.003 μM; IC90 = 0.009 μM) with minimal cytotoxicity .

HY-161270

HIV-1 protease-IN-13	HIV Protease	Infection
HIV-1 protease-IN-13 (compound 18d) is a potent **HIV-1 protease inhibitor with an IC₅₀** value of 0.54 nM. HIV-1 protease-IN-13 also shows potent activity against HIV-1DRVRS (DRV-resistant mutation) and HIV-1NL4_3 variant (wild type) .

HY-14588S2

Lopinavir-d7 ABT-378-d₇	HIV SARS-CoV HIV Protease Isotope-Labeled Compounds	Infection Cancer
Lopinavir-d₇ is deuterated labeled Lopinavir (HY-14588). Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the **HIV-1 protease, with K_is** of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 14.2 μM .

HY-14588R

Lopinavir (Standard) ABT-378 (Standard)	Reference Standards HIV HIV Protease SARS-CoV	Infection Cancer
Lopinavir (Standard) is the analytical standard of Lopinavir. This product is intended for research and analytical applications. Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the **HIV-1 protease, with K_is** of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 14.2 μM .

HY-14588S

(rel)-Lopinavir-d8 (rel)-ABT-378-d₈	Isotope-Labeled Compounds HIV Protease SARS-CoV HIV	Others
(rel)-Lopinavir-d₈ ((rel)-ABT-378-d₈) is the deuterium labeled Lopinavir (HY-14588) . Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the **HIV-1 protease, with K_is** of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 14.2 μM .

HY-17041R

Darunavir Ethanolate (Standard) TMC114 Ethanolate (Standard)	Reference Standards HIV HIV Protease	Infection
Darunavir (Ethanolate) (Standard) is the analytical standard of Darunavir (Ethanolate). This product is intended for research and analytical applications. Darunavir ethanolate (TMC114 Ethanolate) is a potent HIV protease inhibitor used to treat and prevent HIV/AIDS. Darunavir has a Ki of 1 nM for wild type HIV-1 protease.

HY-120331

U-89360E	HIV HIV Protease	Infection
U-89360E is an inhibitor for **HIV-1 protease*. U-89360E inhibits the protease* of HIV-1 wildtype, V82D mutant and V82N mutant with K_i of 20 nM, 560 nM and 2100 nM, respectively .

HY-112585

Darunavir-d9 TMC114-d9; UIC-94017-d9	HIV HIV Protease	Infection Inflammation/Immunology
Darunavir-d9 (TMC114-d9) is the deuterium labeled Darunavir. Darunavir (TMC114), an orally active next generation **HIV protease** inhibitor, has a similar antiviral activity against the mutant and the wild-type viruses. Darunavir (TMC114) is potent against laboratory HIV-1 strains and primary clinical isolates (IC₅₀ = 0.003 μM; IC₉₀ = 0.009 μM) with minimal cytotoxicity .

HY-181888

GRL-142	HIV HIV Protease	Infection
GRL-142 is a potent *HIV-1* protease inhibitor capable of crossing the blood-brain barrier. GRL-142 exhibits extremely high inhibitory activity against both wild-type and multidrug-resistant strains (IC₅₀=0.0094 nM). GRL-142 acts synergistically with the P2/P2' segments via a unique scaffold binding mechanism, utilizes fluorine-mediated stable interactions to maintain its bioactive conformation, adapts to p51 HIV-1 protease mutants, and maintains the flap-closed state by directly acting on the flap tip residues. GRL-142 disrupts the flap-water hydrogen bond network of wild-type protease, thereby effectively blocking viral replication. GRL-142 can be used to study HIV-1 infection and the associated neurocognitive disorder (HAND) .

HY-183562

TMC-126 UIC-94003	HIV HIV Protease	Infection
TMC-126 (UIC-94003) is a non-peptidic HIV-1 protease (HIV-1 *protease) inhibitor. TMC-126 exhibits highly potent antiproliferative activity against wild-type* HIV-1. TMC-126 can be used in studies related to HIV infection ^[1] .

HY-126120

BILA 1906 BS	HIV HIV Protease	Infection
BILA 1906 BS is a *HIV* *protease* inhibitor. BILA 1906 BS prevents *HIV-1* replication via inhibition of viral protease-mediated cleavage of Gag and Gag-Pol polyprotein precursors during virion maturation. BILA 1906 BS blocks maturation of p24 proteins in wild-type HIV-1, impairing polyprotein processing and viral maturation. BILA 1906 BS can be used for the research of human immunodeficiency virus type 1 (HIV-1) infection .

HY-107123R

TMC310911 (Standard) ASC-09 (Standard)	Reference Standards HIV Protease	Infection
TMC310911 (Standard) (ASC-09 (Standard)) is the analytical standard of TMC310911 (HY-107123). This product is intended for research and analytical applications. TMC310911 is a potent and orally active HIV type-1 (HIV-1) protease inhibitor with EC₅₀ values ranged from 2.2 nM to 14.2 nM for wild-type HIV-1. TMC310911 has potent activity against a wide spectrum of recombinant HIV-1 isolates. TMC310911 has strong antiviral activity .

Cat. No.	Product Name	Chemical Structure

HY-14588S1

Lopinavir-d8
Lopinavir-d₈ (ABT-378-d₈) is the deuterium labeled Lopinavir. Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 14.2 μM .

Lopinavir-d8

Lopinavir-d₈ (ABT-378-d₈) is the deuterium labeled Lopinavir. Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 14.2 μM .

HY-14588S2

Lopinavir-d7
Lopinavir-d₇ is deuterated labeled Lopinavir (HY-14588). Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the **HIV-1 protease, with K_is** of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 14.2 μM .

Lopinavir-d7

Lopinavir-d₇ is deuterated labeled Lopinavir (HY-14588). Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 14.2 μM .

HY-14588S

(rel)-Lopinavir-d8
(rel)-Lopinavir-d₈ ((rel)-ABT-378-d₈) is the deuterium labeled Lopinavir (HY-14588) . Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the **HIV-1 protease, with K_is** of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 14.2 μM .

(rel)-Lopinavir-d8

(rel)-Lopinavir-d₈ ((rel)-ABT-378-d₈) is the deuterium labeled Lopinavir (HY-14588) . Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 14.2 μM .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.